Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CBD for LGS: Fewer seizures, but thrombocytopenia risk

Publish date:: October 22, 2020

Key clinical point: Cannabidiol reduces seizures but may cause thrombocytopenia in some patients.

Major finding: Average seizure reduction was greater than 60%, but one-third on valproic acid had thrombocytopenia.

Study details: Open-label extension trial of 366 patients and single-center retrospective study of 83 patients on CBD therapy for Lennox Gastaut syndrome.

Disclosures: Anup D. Patel, MD, disclosed financial relationships with GW Research and Greenwich Biosciences. Nancy A. McNamara, MD, has no relevant disclosures.

Citation:

Patel AD et al. CNS-ICNA 2020, Presentation PL12; McNamara NA et al. CNS-ICNA 2020, Presentation PL29.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Epilepsy & Seizures

Study supports halting antiseizure medications after neonatal seizures,

CBD for LGS: Fewer seizures, but thrombocytopenia risk,

Preventive treatment delays first seizure onset in tuberous sclerosis complex,

Listening to Mozart helps tame epilepsy,

In epilepsy, brain-responsive stimulation passes long-term tests,